Organicell Regenerative Medicine Inc  (BPSR)
Other Ticker:  
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Organicell Regenerative Medicine Inc
Organicell Regenerative Medicine Inc. is a biotechnology company specializing in regenerative medicine. The company focuses on developing innovative therapies using biological products derived from natural sources. Organicell's mission is to harness the healing power of nature to provide effective treatment options for patients suffering from various medical conditions.

The company's research and development efforts are centered around utilizing the regenerative properties of exosomes, which are small extracellular vesicles secreted by cells. These exosomes are rich in growth factors, proteins, and nucleic acids that have the potential to stimulate tissue repair and regeneration.

Organicell aims to develop exosome-based therapies for a range of diseases and disorders, including neurodegenerative conditions, cardiovascular diseases, and orthopedic injuries. By harnessing the potential of exosomes, the company aims to provide safer and more efficient treatment options that can potentially address the underlying causes of these conditions.

Organicell also places a strong emphasis on the safety and efficacy of its products. The company follows rigorous research, development, and manufacturing protocols to ensure the quality and consistency of its therapies. Through collaborations with leading academic institutions and clinical research organizations, Organicell aims to advance the field of regenerative medicine and improve patient outcomes.

In summary, Organicell Regenerative Medicine Inc. is a biotechnology company focused on developing innovative therapies using exosomes derived from natural sources. The company aims to harness the healing power of these biological products to provide effective treatment options for various medical conditions.

   Company Address: 3321 College Avenue Davie 33314 FL
   Company Phone Number: 963-7881   Stock Exchange / Ticker: BPSR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Organicell Regenerative Medicine Inc

Organicell Regenerative Medicine Inc. Overcomes Challenges, Shows Resilience During Recent Fiscal Period

Organicell Regenerative Medicine Inc Reaches Break-Even in Q3 2023
During the third quarter of 2023, Organicell Regenerative Medicine Inc reached a break-even point of $0.00 per share, compared to the same period last year and the preceding reporting period. This achievement indicates the company's ability to generate revenue to cover its expenses.
However, the company experienced a significant decline in revenue, which crumbled by -28.749% to $1.22 million from $1.71 million during the comparable reporting period a year ago. On the positive side, there was a sequential revenue surge of 44.373% from $0.85 million. This indicates that, while the year-over-year comparison may seem negative, the company has seen substantial growth compared to the previous quarter.
Organicell Regenerative Medicine Inc reported a net shortfall of $-1.618 million in the third quarter of 2023, which is an improvement from a deficit of $-2.727 million in the same reporting period a year ago. This reduction in the net shortfall indicates that the company has managed to control its expenses better, leading to a smaller financial deficit.

Organicell Regenerative Medicine Inc

Organicell Regenerative Medicine Inc Suffers Dire Revenue Plunge of Over 50% as Fiscal Interval Concludes April 2023

Organicell Regenerative Medicine Inc, a leading company in the field of regenerative medicine, recently released its financial report for the span closing April 30, 2023. The company demonstrated balanced books, with earnings of $0.00 per share. This figure remained the same as the previous year, and there was no change from the prior reporting season.
However, amidst this seemingly stable financial standing, there was a significant decline in revenue. Compared to the same reporting season a year earlier, Organicell saw a sharp decrease of -51.273%, generating $0.85 million in revenue, down from $1.74 million. Sequentially, the company experienced a -20.997% decrease in revenue, with $1.07 million generated in the prior reporting season.


Organicell Regenerative Medicine Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com